Ignite Creation Date:
2024-05-05 @ 6:34 PM
Last Modification Date:
2024-10-26 @ 9:34 AM
Study NCT ID:
NCT00504842
Status:
TERMINATED
Last Update Posted:
2008-04-15
First Post:
2007-07-18
Brief Title:
Transcranial Ultrasound in Clinical SONothrombolysis
Sponsor:
ImaRx Therapeutics
Organization:
ImaRx Therapeutics
Study Overview
Official Title:
A Phase 1-2 Randomized Placebo-Controlled Single-Blind Dose Escalation Study to Evaluate the Safety Tolerability and Activity of Ascending Single Doses of MRX-801 With Continuous Ultrasound Administration in Subjects With Acute Ischemic Stroke Receiving Treatment With Intravenous Tissue Plasminogen Activator
Status:
TERMINATED
Status Verified Date:
2008-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Sponsor decision
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
TUCSON
Brief Summary:
This is a randomized placebo controlled parallel group dose escalation trial to evaluate the safety tolerability and activity of four sequential dose tiers of MRX-801 and ultrasound as an adjunctive therapy to tissue plasminogen activator tPA treatment in subjects with acute ischemic stroke
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None